Little Green Pharma

At a composite of 54, Little Green Pharma scores as Neutral, with conviction of 2 out of 5 backing the assessment. The composite is a fixed blend of four pillars — fundamentals at 35 percent, regulatory at 25, market at 25, and editorial at 15 — and each contribution is inspectable. The strongest contribution comes from the fundamentals pillar at 75, and pulls the composite into the middle of the band. Editorial lags at 30, softening what would otherwise be a stronger reading.

Working through the numbers, Little Green Pharma shows reported revenue growth of 20.4 percent year over year, an operating margin of 0.0 percent, gross margin of 71.1 percent. Those inputs are the ones that drive the Neutral anchor rather than sentiment. Every input flowing into the pillar table comes from primary regulatory filings, licensed fundamentals data, and institutional pricing feeds, filtered through CIN newsroom density. The 336-ticker CIN universe is scored deterministically, so Little Green Pharma can be compared against the global cannabis coverage universe on identical inputs, refreshed on the ingest cycle.

The forward path is set by fundamentals, which carry 75 of this rating. A quarterly print showing revenue above the trailing four-quarter run rate — paired with a defensible operating margin — would justify a tighter band; the reverse would loosen it.